Answers are grounded in this paper and cite their sources.
Demonstrates inhibitory activities of Bauhinia brachycarpa extracts in multitarget enzyme systems, suggesting therapeutic potential.
= 5.39 ± 0.30 μM) and acted as a mixed-type inhibitor (Ki = 0.29, Kis = 21.3), with stronger affinity for the free enzyme. Its binding mode and conformational stability were further elucidated by molecular docking and molecular dynamics simulations. Among the known isolates, quercetin (8) and afzelin (12) showed moderate inhibitory activities against both α-glucosidase and pancreatic lipase. This work enriches the chemical and pharmacological knowledge of B. brachycarpa and underscores its potential as a source of multitarget enzyme inhibitors.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: